News

New data from ESMO Breast 2025 indicate that inherited DNA repair mutations could affect the effectiveness of CDK4/6 inhibitors in treating advanced breast cancer, with mutation carriers showing lower response rates and shorter survival trends.

The PHECDA trial evaluated stapokibart as an add-on therapy during pollen season in adults with moderate-to-severe seasonal allergic rhinitis.

Ten-year data show complete revascularisation reduces repeat procedures in STEMI patients with multivessel disease.

PLAN-B-DF was trained and internally validated on a large cohort of 5,585 patients, and externally validated.

New data presented at ESMO Breast 2025 show that short-course radiotherapy offers similar survival outcomes to conventional treatment following surgery and nodal irradiation for breast cancer.

New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma receiving bispecific antibodies…

Research shows that regular physical activity can help close the survival gap for stage III colon cancer, with those who exercise achieving survival rates similar to the general population.

This dramatic decline highlights the success of interventions such as oral rehydration therapy, rotavirus vaccination, and improvements in water and sanitation.